Prevention

The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending October 29, 2023.

Staying Ahead With Company Updates and Product Innovations. This week's news is from Moderna, CBIC, Helocyte, Pfizer, UVDI, and CloroxPro.

A study led by Piyali Chatterjee, PhD, and the Central Texas Veterans Health Care System explores the potential of handheld filtered Far UV-C devices in reducing hospital-acquired infections. Freestyle Partners, LLC, supported this research.

A recent American Journal of Infection Control study, led by Katharine Hoffman, MPH, CIC, LSSGB, and Lisa Waldowski, DNP, RN, CIC, applies Lean Six Sigma to improve eye device reprocessing. The research highlights the challenges, emphasizes adherence to manufacturer instructions, and promotes best practices for patient safety.

Benjamin Chen, MD, MPH, speaks about how a journal watch in infection prevention keeps professionals updated on research, fosters evidence-based practices, and supports education and quality improvement efforts.

ICT speaks with Christopher Reid, PhD, a biological and biomedical Sciences professor, delving into his investigations on antibiotics and fungicides and how his team's investigations will "provide an extra tool in a clinician's" toolbox for treating bacterial fungal infections."

“Celebrate Clean Hospitals Day with us. We're an association that is trying to get out there and make people's lives a bit safer and better. Join us!” Alexandra Peters, PhD

The Executive Director of the Certification Board of Infection Control and Epidemiology (CBIC) addresses the eligibility guidelines for the Certification in Infection Prevention and Control (CIC) examination. While designed for success, these guidelines are not requirements, ensuring inclusivity for candidates from diverse infection prevention backgrounds. The CBIC emphasizes readiness and offers support to prospective CIC candidates.

Recent INFORM and EPOCH studies shed light on the significant risk and poor outcomes faced by immunocompromised individuals due to COVID-19, emphasizing the need for tailored prevention strategies.

Infection Control Today analyzes the surprising findings from its recent informal survey on the minimum educational requirement for infection preventionists.

At IDWeek 2023, a presenter uses HIV as a model to understand the post-acute sequelae of viral infections.

At IDWeek 2023, a session illuminates the importance of accurate diagnosis, current treatments, and what is on the horizon for HSV.

International Infection Prevention and Control Week highlights the importance of preventing infections in health care and other settings. Share this poem to help educate others about IPC.

Building Information Modeling (BIM) plays a pivotal role in designing health care facilities that minimize infection risks, promoting efficient planning, and coordination while reducing construction challenges.

The latest news on CLABSIs in the pediatric population is presented at IDWeek 2023.

At IDWeek 2023, a look into managing VAIs in children.

An immunocompromised keynote speaker, Kevin Kavanagh, MD, shares strategies for safe air travel during the COVID-19 pandemic, emphasizing mask usage, vaccinations, and air quality monitoring, with mixed observations throughout the journey.

A study of 28 nursing homes and nearly 29,000 residents reveals that universal decolonization significantly lowered infection-related hospitalizations, offering hope for improved healthcare outcomes.

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending October 15, 2023.

A study in Maryland from June 2019 to December 2021 analyzed 140 Candida auris cases, revealing that patients often resided in disadvantaged neighborhoods with higher crowding, uninsured rates, and racial diversity. ICT speaks to the lead author.

A phase 3 trial presented at IDWeek 2023 shows that sulbactam-durlobactam (SUL-DUR) reduces mortality and improves outcomes in hospital-acquired Acinetobacter baumannii-calcoaceticus complex infections compared to colistin, offering a promising treatment option.

Infection Intel is a new column for Infection Control Today® (ICT®) that will cover the latest news, including updates on product developments, mergers, and more from companies in the infection control and prevention field.

Dr. Isaac Kohane explores AI's rapid medical evolution and the challenges of accuracy, updating, and education in infectious diseases at IDWeek 2023.

BiomX Develops BX004-A, a Phage Therapy, for Cystic Fibrosis Patients with Pseudomonas Infections. A phase 1b/2a study presents promising results at IDWeek 2023.